4basebio PLC announced a Joint Development Agreement with Heqet Therapeutics S.r.l. This JDA is focussed on the development of a non-viral vector, incorporating a proprietary Heqet payload for cardiomyocyte regeneration and treatment of myocardial infarction more broadly. Under the JDA, the companies will evaluate the use of 4basebio's Hermes™ non-viral nanoparticle for the delivery of payloads targeting cardiomyocyte regeneration. The successful outcome of this project may lead to the proof-of-concept development of a therapy enabling heart regeneration post infarction.